PNC:NYSEPNC Financial Services Group, Inc. (The) Analysis
Data as of 2026-03-10 - not real-time
$205.34
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
PNC is trading at $205.34, notably below its 20‑day ($223.19) and 50‑day ($221.61) simple moving averages, yet it remains above the 200‑day SMA ($199.09), indicating a longer‑term bullish backdrop. The RSI of 32 signals oversold conditions, while the MACD remains in a bearish divergence, suggesting short‑term downside pressure may be limited. Fundamentally, the bank posted record Q4 2025 revenue with an 8% year‑over‑year increase, net income of $2.0 B and EPS of $4.88, and operating leverage improved by 5%, reinforcing its earnings momentum. Valuation appears mixed: a PE of 12.38 is well below the industry average of 17.38, supporting a value case, yet the DCF‑derived fair value of $43.54 is far beneath the current price, flagging potential overvaluation. The dividend yield of 3.3% with a 39.8% payout ratio is comfortably sustainable given the $14.5 B cash position.
Analyst sentiment is upbeat – Keefe Bruyette raised the price target to $247 and the consensus recommendation is a “Buy” with a median target of $251. The stock’s beta of ~0.95 and a 30‑day volatility of ~30% signal market‑aligned risk, while rising volume underscores growing investor interest. With solid cash generation, a disciplined share‑repurchase program, and inclusion on dividend‑contender lists, PNC offers a compelling blend of income and growth, though short‑term technical weakness and valuation concerns warrant a measured approach.
Analyst sentiment is upbeat – Keefe Bruyette raised the price target to $247 and the consensus recommendation is a “Buy” with a median target of $251. The stock’s beta of ~0.95 and a 30‑day volatility of ~30% signal market‑aligned risk, while rising volume underscores growing investor interest. With solid cash generation, a disciplined share‑repurchase program, and inclusion on dividend‑contender lists, PNC offers a compelling blend of income and growth, though short‑term technical weakness and valuation concerns warrant a measured approach.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicating oversold conditions
- Price near key support at $198.04
- Bearish MACD suggesting limited upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Record revenue and EPS beat
- Analyst price target lift to $247
- Sustainable 3.3% dividend yield
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong cash position and dividend sustainability
- Long‑term earnings growth from rate tailwinds
- Potential overvaluation relative to DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth9.60%
Profit Margin31.08%
P/E Ratio12.4
ROE12.16%
ROA1.23%
P/B Ratio1.5
Op. Cash Flow$4.4B
Industry P/E17.4
Technical Analysis
TrendBullish
RSI32.2
Support$198.04
Resistance$243.65
MA 20$223.19
MA 50$221.61
MA 200$199.09
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Fair Value$43.54
Target Price$251.90
Upside/Downside22.68%
GradeOvervalued
TypeBlend
Dividend Yield3.30%
Risk Assessment
Beta0.95
Volatility29.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.